Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia

• References

• 1 Neerman-Arbez M, de Moerloose P, Bridel C. et al. Mutations in the fibrinogen alpha gene account for the majority of cases of congenital afibrinogenemia. Blood 2000; 96: 149-52.
• 2 Lak M, Keihani M, Elahi F. et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107: 204-6.
• 3 Bamatter F, Fanconi G, Freudenberg E. et al. Kongenitale Afibrinogenaemie. Helvetica Pediatrica acta 1963; 18: 208-28.
• 4 Dupuy E, Soria C, Molho P. et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102: 211-9.
• 5 Cronin C, Fitzpatrick D, Temperley I. Multiple pulmonary emboli in a patient with afibrinogenaemia. Acta Haematol 1988; 79: 53-4.
• 6 De Vries A, Rosenberg T, Kochwa S. et al. Precipitating anti fibrinogen antibody appearing after fibrinogen infusion in a patient with congenital afibrinogenaemia. Am J Med 1961; 30: 486-94.
• 7 Watanabe K, Shibuya A, Ishii E. et al. Identification of simultaneous mutation of fibrinogen alpha chain and protein C genes in a Japanese kindred. Br J Haematol 2003; 120: 101-8.
• 8 De Mattia D, Regina G, Giordano P. et al. Association of congenital afibrinogenemia and K-dependent protein C deficiency -a case report. Angiology 1993; 44: 745-9.
• 9 de Bosch NB, Mosesson MW, Ruiz-Saez A. et al. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost 2002; 88: 253-8.
• 10 Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution. Clin Invest 1994; 72: 396-8.
• 11 Cattaneo M, Bettega D, Lombardi R. et al. Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasma. Br J Haematol 1992; 82: 388-90.
• 12 Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 544-52.
• 13 Cattaneo M, Kinlough-Rathbone RL, Lecchi A. et al. Fibrinogen-independent aggregation and deaggregation of human platelets: studies in two afibrinogenemic patients. Blood 1987; 70: 221-6.
• 14 Ni H, Denis CV, Subbarao S. et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-92.
• 15 Ni H, Yuen PS, Papalia JM. et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. PNAS 2003; 100: 2415-9.
• 16 Siegmund B, Richter H, Pollmann H. Prophylactic treatment of afibrinogenemia with the fibrinogen concentrate Haemocomplettan. J Thromb Haemost 2003; 01 Abstract P0270.